Xlife Sciences AG (XLS DE, Xetra) acquires a 50% stake in palleos healthcare GmbH, Wiesbaden, Germany. Based on an approximate valuation of the company at EUR 10.0 million, the acquisition price is EUR 4.0 million and 40,000 shares of Xlife Sciences AG. Specific milestones have been agreed upon for the final settlement date and acquisition price, specific milestones have been agreed upon. The notarization of the share purchase and transfer agreement as well as the capital increase was executed today.

About palleos healthcare GmbH

palleos healthcare GmbH is a full service clinical research organization (CRO) based in Wiesbaden, Germany, providing services for drug development as well as sponsorship services in all study phases. A specific focus is the implementation of preclinical and translational concepts in early phases of clinical development.
Through the CRO-Alliance ONE, palleos extends its reach to Eastern, Western Europe and the USA. The strategic alliance with Phaon scientific enables the implementation of academic concepts. Within Germany, palleos cooperates with more than 250 study centers and has implemented phase I-IV studies with more than 15,000 patients. Overall, palleos' aim is to build a regulatory and operational bridge between preclinical and clinical development to implement innovative concepts for its customers.
For more information, please visit: www.palleos.com

About Xlife Sciences AG

Xlife Sciences AG (XLS DE, Xetra) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch